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ABSTRACT



RESUM
E

Background: Extracorporeal life support (ECLS) is associated with high
morbidity and mortality. Complications and mortality are higher at
lower-volume centres. Most Canadian ECLS institutions are low-volume
centres. Protocols offer one way to share best practices among institutions to improve outcomes. Whether Canadian centres have ECLS
protocols, and whether these protocols are comprehensive and homogenous across centres, is unknown.
Methods: Purposeful sampling with mixed methods was used. A
Delphi panel deﬁned key elements relevant to the ECLS process.
Documentation used in the delivery of ECLS services was requested
from programs. Institutional protocols were assessed using deductive
coding to determine the presence of key elements.
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The use of extracorporeal life support (ECLS) has increased in
the past 2 decades. Extracorporeal membrane oxygenation
(ECMO), a common form of ECLS, is associated with high

morbidity and mortality,1 with variable survival to discharge
of 60%, 43%, and 29% for veno-venous (VV)-ECMO, venoarterial (VA)-ECMO, and extracorporeal cardiopulmonary
resuscitation (eCPR) cases, respectively.2 In keeping with evidence from other areas of medicine, a low frequency of cases
may contribute to poor outcomes.3 In Canada, more than half
of ECLS centres perform fewer than 10 VV-ECMO and 10
VA-ECMO cases annually.4 Similarly, in Germany, the majority of ECLS cases are done in lower-volume centres (< 50
VA ECMO cases/year) despite higher complication rates and
mortality in these centres.5 Although limiting ECLS to centres
of excellence will increase case numbers and concentrate
expertise, the emergent nature of ECLS and the expansiveness
of Canadian geography mean that ECLS will continue to be
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Results: A total of 37 key elements spanning 5 domains (referral,
initiation, maintenance, termination, and administration) were identiﬁed. Documentation from 13 institutions across 10 provinces was
obtained. Institutions with heart or lung transplantation programs had
more-complete documentation than did non-transplantation programs.
Only 5 key elements were present in at least 50% of protocols (anticoagulation strategy, ventilation strategy, deﬁned referral process,
selection criteria, weaning process), and variation was seen in how
institutions approached each of these elements.
Conclusions: The completeness of ECLS protocols varies across Canada. Programs describe variable approaches to key elements. This
variability might represent a lack of evidence or consensus in these
areas and creates the opportunity for collaboration among institutions
to share protocols and best practice. The key-element framework
provides a common language that programs can use to develop ECLS
programs, initiate quality-improvement projects, and identify research
agendas.
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offered at smaller centres and will remain a high-stakes
low-frequency event. Given this constraint, alternative solutions to improve ECLS outcomes are needed.
Standard ECLS protocols may help reduce variation in care
between larger and smaller centres and have the potential to
improve patient outcomes. In some instances, a hub-andspoke relationship exists, whereby smaller institutions may
feed cases to larger centres. Harmonization of ECLS protocols
could positively impact patient care consistency. Additionally,
standard protocols for ECLS referral and initiation shorten the
time to initiation,6 which in turn is associated with improved
survival.7
Although direct evidence between protocol use and improved
ECLS outcomes is lacking, it seems intuitive that implementing
standard protocols may beneﬁcially inﬂuence outcomes for these
high-stakes low-frequency events and warrants further investigation. Notably, in other complex industries, establishing
emergency operating procedures is an important component of
ensuring safety and quality improvement.8,9
A recent survey of Canadian centres offering ECLS showed
that programs lacked protocols for important aspects of ECLS
delivery, despite offering these services (eg, eCPR).4 For centres
with protocols, only limited data are available to guide which
elements should be included and their implementation.10-12
Better characterization of existing protocols and an understanding of their usage within Canadian programs could
improve ECLS service delivery across the nation.
In this study, a Delphi process (further described in the
Materials and Methods section) established key elements to
include within ECLS protocols. The prevalence of these key
elements was determined, and areas of consensus and uncertainty within existing ECLS program documentation
from 13 Canadian centres were described. These results
provide much-needed evidence regarding the current state of

ECLS programs across Canadian centres, highlighting areas
for future research and quality improvement.
Materials and Methods
Study design
The study was reviewed by the Western University Health
Sciences Research Ethics Board, and the board determined
that board oversight is not required. We employed mixed
methods to characterize the current state of Canadian ECLS
protocols. Utilizing a list of Canadian institutions deemed
capable of delivering ECLS services from previous unpublished work, program leads were contacted via e-mail to
request documentation related to ECLS delivery (eg, policy
and procedures, order sets, protocols, etc). Document analysis
required determination of important criteria to include within
protocols (eg, anticoagulation protocol, ventilation protocol,
etc). A Delphi panel was used to deﬁne these key elements.
Documentation was analyzed for the presence of key elements, and areas of consensus and uncertainty were described.
Delphi panel methods
Given the lack of consensus outlining ideal Canadian
ECLS protocol content, a Delphi panel was created to identify
key elements that should be included. The RAND/University
of California, Los Angeles Delphi Method used in similar
studies was adapted for this project.13,14 A 9-member panel
with expertise in critical care, cardiac surgery, cardiology,
emergency medicine, and internal medicine was assembled for
this process. Panel members represented relevant disciplines,
geographic distribution, and institution types, including lung
transplantation, cardiac transplantation, and cardiac surgery
programs. The process was anonymous and was delivered

522

CJC Open
Volume 4 2022

Table 1. Characteristics of Delphi panel
Specialty training of panelist
Years in practice

Number of members

Gender

Cardiac surgery

Cardiology

Critical care

Emergency medicine

4
2
3

3 male, 1 female
2 male
3 male

1
1
2

2
d
d

3
2
2

1
d
1

<5
5e10
> 10

electronically over 3 rounds. Table 1 provides characteristics
of the Delphi panel.
Round 1 asked panel members to identify key elements of
the ECLS protocol/program manual. Panel members were
provided with documentation explaining the purpose of the
research project, examples of possible key elements and how
they will be used in the study, and relevant literature.10-12
Panelists were asked to identify any and all relevant key
elements.
Round 2 of the Delphi process consisted of a survey that
asked panelists to rate the importance of key elements
generated in round 1. Similar key elements were combined
along with descriptions. A 9-point Likert scale was used, and a
key element was considered important if it obtained a median
score of 7 or more.13 Panelists were required to provide
rationale for scores of 5 or lower.
Round 3 required panelists to approve the ﬁnal list of key
elements. Panelists were provided with a list of approved and
rejected key elements with low score rationale. All members
approved of the ﬁnal list without the necessity of further
rounds.
Protocol sampling
Contact information for program leads was available for 24
institutions from previous work. Program leads were contacted via e-mail and provided with the rationale for the
project. Any documentation related to the delivery or
administration of ECLS services was requested. Program leads
were recontacted at regular intervals until a representative
sample was obtained. A geographically diverse sample, representing ECLS-capable institutions was targeted, incorporating
programs with differences in volume and programdevelopment robustness. Centres were categorized as heartlung transplantation capable, heart transplantation capable,
and cardiac surgery only capable. Programs were recontacted
until representation from all provinces was obtained.
Analysis
Deductive coding was used to analyze documents for the
presence or absence of key elements. The key elements and
their descriptions were used as a coding framework.15 A key
element was coded as present if the element was directly
mentioned (eg, anticoagulation protocol), or if indirect evidence that it existed was present (eg, some documents had
approval stamps, suggesting a regular internal review process).
Any text that did not meet the predeﬁned coding framework
was highlighted through inductive coding, and a memo
journal was maintained throughout the process.
These data were used to determine the completeness of
protocols by institution type. Additionally, key elements were
grouped by their prevalence across protocols. Key elements
that were present in more than 50% of institutional protocols

underwent further analysis. The coded data from each key
element were extracted from the original protocols and organized by key element code. These data then underwent
narrative description.
To ensure reliability of coding, 2 authors independently
reviewed the coded protocols for accuracy. Member checking
was also employed to ensure validity.16 The results and
analysis were shared with the Delphi panel prior to publication. Delphi panel members represented stakeholders familiar
with ECLS programs, with intimate knowledge of their
institutional protocols. This group also contained representation from the Canadian Cardiovascular Critical Care Society
and the Canadian Critical Care Society.
Results
The Delphi process occurred over 4 months and yielded 37
key elements identiﬁed as important components of an ECLS
protocol (Table 2). These were broadly classiﬁed into 5 domains of the ECLS process (referral, initiation, maintenance,
discontinuation, and administrative). The ﬁnal list was
approved by all 9 members of the panel.
There are 39 institutions in Canada capable of delivering
ECLS.4 Program documentation was obtained from 13 institutions (33%), representing all provinces, 2 of 4 lung/heart
transplantation centres (50%), 5 of 11 heart transplantation
centres (without lung transplantation; 45%), and 6 of 24
cardiac surgery-only centres (25%). The documents that were
provided varied among centres and included practice guidelines, protocols, policies and procedures, and order sets. Two
programs lacked any documentation but were in the process
of developing protocols. Four programs provided documentation organized into “program manuals.”
Only 3 programs had documentation that included greater
than 50% of the 37 key elements. Of these, one had a
complete program manual in a single document that described
roles and responsibilities, clinical management, relevant policies, and order sets. Two programs had a collection of clinical
guidelines outlining the care process for speciﬁc ECLS phases
(eg, initiation, weaning, etc). These documents provided clear
roles and responsibilities of all team members, as well as the
clinical rationale for appropriate management and troubleshooting during those phases. All centres that had more
comprehensive documentation were either heart and/or lung
transplantation capable centres (Fig. 1).
In regard to the programs with less-comprehensive documentation, variability was seen in the key elements that were
addressed and in how they were addressed. Some programs
had robust emergency ECLS procedures, whereas others had
very detailed order sets with step-by-step nursing instructions.
In contrast to comprehensive program manuals, these documents seemed more sporadic in the issues that were addressed.
Documents more commonly focused on the roles of
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Table 2. List of domain and key elements identiﬁed by Delphi panel
Key element followed by description
Referral phase
Patient selection criteria
Inclusion/Exclusion for respiratory failure, cardiac arrest, and cardiogenic shock
Shock team
Who evaluates referral? Single person on call, medical director, panel of experts, ECMO team/specialist, or dedicated
shock team?
Deﬁned referral process
Presence of algorithms to assist with rapid decision making, speciﬁc referral process for each indication, process for EMS
referral or interhospital referral
Prehospital protocol
EMS referral and resuscitation process, process for transition from ACLS to ECLS
Initiation phase
Initiation process
Deﬁned location and process, speciﬁcally addressing cannula choice, heparin timing and route, cannulation site, etc.
Peripheral hospital initiation
Process for mobile ECLS team, interhospital transport, etc.
Identiﬁed roles and responsibilities
Who should be present, roles, training, ACLS vs ECLS team, speciﬁc cannulators?
Cannulation protocol
Who should do it? Preference for speciﬁc sites, choice of cannula sizes, sedation and paralysis during cannulation
Anticoagulation
Type and timing during cannulation
Checklists
Equipment and actions to be performed including role assignments, and potential plan for after-action reviews
Consent process
Is consent required? Should it be? How is it obtained?
Post-initiation procedures
Deﬁned process for post-initiation procedures such as cath lab activation, lower-extremity reperfusion, intensive care
unit parameters, etc.
Maintenance phase
ECMO circuit monitoring
How does general system monitoring and maintenance occur (eg, clots, pressures, etc). Who is responsible for this?
Anticoagulation
Choice of maintenance anticoagulation and monitoring parameters. Management of potential challenges (heparin
resistance), monitoring for complications (clots, heparin-induced thrombocytopenia, bleeding) and periprocedural
anticoagulation management.
Hemodynamic management
Targets for hemodynamic support, choice of inotropes/vasopressors, and ﬂuid management
Ventilator management
Ventilator management speciﬁc for each indication (eg, respiratory vs cardiac failure). Initial management and overall
guiding principles.
Temperature management
Does cooling occur post-arrest; how does it occur?
Bleeding management
Is there a protocolized approach to address bleeding?
Emergency protocols
Do protocols exist for predictable emergencies (eg, accidental decannulation, thrombosis, etc.)?
Intrahospital transport protocol
How are patients transported safely, who is responsible?
Deﬁned process for LV unloading
Is there a deﬁned process for when and how this occurs?
MCS/shock team
Daily rounds, MRP, etc.
Mobilization strategy
Is there a deﬁned strategy for safe PT and mobilization of ECLS patients?
Discontinuation phase
Weaning protocol
How, where, and parameters that prompt weaning including associated changes in ventilator settings and/or
hemodynamic support
Process for device transition
Is there a deﬁned process for device transition (eg, durable ventricular assist device, central ECMO, etc.)
Discontinuation of anticoagulation
Heparin reversal, transition to DVT prophylaxis
Prognostication
Expected duration, neuroprognostication, deﬁnition of futility
End-of-life planning
Deﬁned process for recognizing this, approaching it with family, etc.
Organ donation/procurement
Process for declaration, approach to family, procurement, etc.

Prevalence in protocols, %
50
25
58
17
33
8
25
33
33
25
17
33

50
75

17
58
17
17
42
17
8
42
25
58
0
0
33
17
17
Continued
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Table 2. Continued.
Key element followed by description

Prevalence in protocols, %

Administration phase
Education
Certiﬁcation, maintenance of competency, including simulation of common challenges
Quality assurance
Annual review, annual reports, comparison against established registries
Availability of clinical expertise
Availability of appropriate clinical expertise (ie, surgical services, perfusion, PCI capacity, etc.)
Additional support services
Ethics, pastoral care, etc.
ECLS committee/governance
Formal administrative structure in place for monitoring and administration of ECLS program
Research program
Data reporting, ELSO database, etc.
Partnership with prehospital organizations
Appropriate partnership with relevant stakeholders
Appropriate protocols in place prior to program initiation
Do relevant protocols exist prior to offering ECLS services (ie, inclusion criteria and referral process, etc.)

17
25
42
17
33
8
8
42

ACLS, advanced cardiac life support; DVT, deep vein thrombosis; ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation; ELSO,
extracorporeal life support organization; EMS, emergency medical services; LV, left ventricular; MCS, mechanical circulatory support; MRP, most responsible
physician; PCI, percutaneous coronary intervention; PT, physical therapy.

non-physician team members (eg, nursing, perfusion, and
respiratory therapy).
Descriptive review of common key elements
Figure 2 shows the prevalence of the 10 most common key
elements. Five key elements were present in more than 50%
of protocols (referral process, patient selection criteria, anticoagulation, ventilator management, and weaning protocol).
Tables 3 through 9 provide detailed description of how each
key element was addressed by the institutions. Programs
varied in how they address anticoagulation and ventilator
management. Less variability was seen in how institutions
addressed the key elements of patient selection, weaning
protocol, and referral process.
Referral process and patient selection
Program documents contained similar inclusion/exclusion
criteria across programs (Tables 3-5). Speciﬁc inclusion/
exclusion criteria of each institution are listed in Tables 4 and
5. The referral process for ECMO is initiated through cardiac
surgery at most institutions. A limited number of institutions
have protocols in place for automatically notifying all team
members once a potential candidate for ECMO has been
identiﬁed.
Anticoagulation and ventilator management
Most programs used unfractionated heparin for routine
anticoagulation (Tables 6 and 7). One program used lowmolecular-weight heparin as a subcutaneous injection for
daily maintenance in select patients. Variation was seen in bolus
dosing for cannulation (5000-30000 units), monitoring (activated clotting time vs partial thromboplastin time [PTT]) and
targets for maintenance (activated clotting time: 160-250 s;
partial thromboplastin time: 50-70.9 s). Only one program
speciﬁcally addressed monitoring and management of
coagulopathy.
Ventilator strategies generally focused on initial parameters rather than guidance related to a more longitudinal

strategy (ie, maintenance and weaning). Most programs
suggested an initial “lung protective strategy”; however,
variation occurred in how this was deﬁned (peak inspiratory
pressure: 20-30 cm H2O; positive end expiratory pressure: 515 cm H2O; tidal volume: 3-4 vs 4-6 mL/kg; inspired
fraction of oxygen 0.3-0.5). Some programs speciﬁed only
that management should be left to the discretion of the
treating team. No programs speciﬁcally addressed ventilation
strategy for VA-ECMO.
Weaning protocol
Most programs described a strategy to safely facilitate a
weaning trial and recommended daily assessment for consideration of weaning (Tables 8 and 9). Programs provided morespeciﬁc criteria for determination of successful weaning from
VV-ECMO compared to VA-ECMO. For VA-ECMO, programs suggested echocardiographic assessment on very low
ﬂow (1.5 LPM). One program (institution 4) provided speciﬁc hemodynamic and echocardiographic criteria for
consideration of a successful VA-ECMO wean.
Discussion
Using a Delphi process involving key stakeholders from
across Canada, 37 key elements spanning 5 domains that
should be included in ECLS protocols were identiﬁed. These
key elements represent important areas to be addressed by an
institution delivering ECLS services. The prevalences of key
elements in existing ECLS protocols from 13 Canadian
institutions were then assessed. Only 5 key elements were
present in more than 50% of protocols. The prevalence of key
elements in documentation varied across centres, with a
higher prevalence found in centres with heart and/or lung
transplantation programs. Given that the majority of ECLS
cases are done at lower-volume centres in Canada,4 and lowervolume centres have been shown to have worse outcomes,5
this study identiﬁed potential areas for quality-improvement
initiatives aimed at increasing protocol completeness and
harmonization across institutions.
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Figure 1. Number of key elements present in institutional protocols. Number of key elements by type of centre: HL; HT; and CS. Red bars represent
transplantation-capable centres; blue bars represent CS centres.

The identiﬁcation of domains and key elements of ECLS
provides a workable framework for program development and
quality-improvement initiatives. Although programs may use
the key-element framework to develop local protocols, this
study could be taken as an opportunity to begin collaborating
on a national ECLS program manual and outcome sharing.
This collaboration should promote information sharing across
programs and reduce the burden on individual institutions as
program development evolves.
Many important areas of the ECLS process remained unaddressed by the majority of institutions. Key elements in the
initiation and program administrative domains were underrepresented. Program administration, including a deﬁned

process for program review, quality improvement, and team
education are essential tenets of the ELSO Centre of Excellence Criteria.17 Key elements dealing with urgent and
emergent aspects of ECLS delivery (ie, initiation, emergency
troubleshooting, etc.) should be protocolized. Predictable
emergencies should not be dealt with on an ad hoc basis. A
common practice in other industries is to develop protocols
for predictable high-stakes events.8,9 Although key elements in
these areas were underrepresented, some programs did have
robust protocols that could be adapted to other institutions.
National collaboration on program development using the
key-element framework would allow centres to share best
practices and learn from other institutions.

Figure 2. Prevalence of key elements found in protocols. ECMO, extracorporeal membrane oxygenation; MCS, mechanical circulatory support.

CVICU, intensive care unit; ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation; eCPR, extracorporeal cardiopulmonary resuscitation; ICU, intensive care unit; MRP, most responsible
physician; VA, veno-arterial; VAD, ventricular assist device; VV, veno-venous.

eCPR activation form that
includes inclusion vs
exclusion criteria and
speciﬁc process for code
eCPR activation (eg,
who to call, room setup,
etc.)
Well-deﬁned referral
process in ﬂow chart
form.
Speciﬁc pathways for
urgent vs emergent and
cardiac vs respiratory
failure.
Provides inclusion/
exclusion criteria,
contact information,
team members and
process for transfer vs
mobile ECLS.
Deﬁned referral process
speciﬁc to COVID19
pandemic.
Flow chart outlining
referral process,
including inclusion/
exclusion criteria and
location-dependent
activation pathway.
ECMO triage team
consists of relevant oncall personnel (eg,
surgeon on call, ICU
consultant, perfusion,
etc.).
This 6e7 member team
must approve all ECMO
activations and is
responsible for
overseeing active cases.
Requests cardiac
surgery
consultation for
VA- and VVECMO.
Mentions VAD
team should also
be consulted for
VA-ECMO.
For nonemergent cases,
consensus between 2
consultant physicians
(on-call surgeon)
separate from MRP is
required.
Referral checklist that
includes speciﬁc
indications,
contraindications, risk
score calculations, and
access-site availability.

Requires consensus of
VAD team, CVICU,
and cardiac surgery
before proceeding with
initiation of ECLS.
Provides some guiding
principles, including
discussion around
cardiogenic shock vs
sepsis, eCPR and post
emitral valve surgery.

Process for
emergency
department
initiation is
identiﬁed.
Emergency
physician is to
notify ICU
consultant who
will coordinate
with required
services (eg,
perfusion,
cardiac surgery,
interventional
cardiology).

Institution 12
Institution 7
Institution 6
Institution 5
Institution 3
Institution 2
Institution 1

Table 3. Key-element narrative reviewddeﬁned referral process

Clearly deﬁned
referral process
initiated through
the on-call
cardiac surgeon
who provides
initial screening
before ECLS
team is
activated.
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We found that heart and/or lung transplantation centres
had more complete protocols. Given that transplantation
centres also have a higher volume of ECLS cases, compared
with nontransplantation centres, protocol completeness likely
reﬂects the need for a clearly deﬁned structure and organization with respect to roles and responsibilities of ECLS stakeholders at each centre. Lower-volume centres may rely on a
more ad hoc approach to delivery of ECLS services when cases
arise. Although direct evidence linking protocol completeness
and better ECLS outcomes at higher volume centres is lacking, national collaboration and sharing of best practices among
institutions may be one avenue to ensure that similar highquality care is delivered at all Canadian institutions.
The narrative review of the 5 common key elements
provides readers with a summary of how institutions
approached these components of ECLS delivery. Key elements with signiﬁcant consensus may indicate higherquality evidence or agreement on an accepted standard of
care. For example, agreement was reached on the criteria for
patient selection, which may reﬂect accepted transplantation
criteria.18 However, key elements with variability may
represent areas of uncertainty. This uncertainty is evident in
the key elements addressing anticoagulation and ventilation.
Anticoagulation strategies show variation in drugs, dosing,
and monitoring. Few programs addressed the management
of coagulopathy associated with ECLS. This variability is
seen internationally and may reﬂect uncertainty in the evidence related to anticoagulation on ECMO.19-21 Similar
uncertainty remains around ideal ventilatory practices for
VV- and VA-ECMO.12,22,23 This variation in practice may
represent an opportunity for future research and qualityimprovement initiatives. It also highlights the need for
outcome tracking in order to effectively implement such a
program.
This study faced several limitations. The Delphi panel
represented many of the institutions that shared documentation for the study, and the representative sample chosen may
have led to sampling bias. This bias was minimized by
ensuring representation from all provinces and also that at
least 2 samples from each type of institution (lung and heart
transplantation capable, heart transplantation capable, and
cardiac surgery-only capable) were represented. Additionally,
better characterization of the participating centres (eg, ECLS
volume, academic vs community, geographic location) could
have enriched the analysis and represents a limitation of this
study. Also, it was impossible to verify that all program
documentation was shared. Using ECLS leads or physicians
with signiﬁcant involvement in ECLS programs who would
have the most familiarity with documentation should have
mitigated this shortcoming. Finally, clinical practice may vary
from what is described in program documentation.
Conclusion
Using an interdisciplinary panel, 37 key elements across 5
domains were identiﬁed that should be incorporated into
ECLS protocols. Assessment of program documentation from
Canadian institutions showed variability in the number of key
elements included in protocols and how protocols addressed
speciﬁc key elements. Further exploration of this variability
could improve clinical care. The key-element framework

Indications:
Cardiogenic shock with
evidence of ongoing
malperfusion
eCPR and post-cardiotomy
ECMO in highly
selected patients.
Contraindications:
Not a transplant or VAD
candidate (eg, cirrhosis,
psychosocial issues)
Sepsis is a relative
contraindication
SAVE score less than e 10
Relative
contraindications:
Nonrecoverable advanced
comorbidity such as
major CNS damage or
terminal malignancy
Contraindication to
anticoagulation (eg,
recent CNS hemorrhage
or large ischemic stroke)
Age > 75 y

Institution 2
Indications:
Suggests referral for
INTERMACS 1 and 2
or refractory cardiogenic
shock
Suggested indications
include post-cardiotomy
shock, acute MI, acute
myocarditis, acute PE,
circulatory support for
PCI, preoperative
support as a bridge to
surgery, acute
decompensation of
chronic
cardiomyopathy, severe
accidental hypothermia
Contraindications:
None speciﬁed

Institution 5
Indications:
Witnessed cardiac arrest,
refractory to
conventional ACLS
Reversible etiology (eg,
ACS, refractory
dysrhythmia, PE, toxic
ingestion, structural
heart disease)
Age < 65 y
Refractory cardiogenic
shock or recurrent
arrests
Contraindications:
Delay in CPR > 5 min
Duration of resuscitation
> 45 min
Signiﬁcant pre-existing
organ failure, active
malignancy or DNR
Active hemorrhage

Institution 6

Institution 7

Institution 12

Institution 13

Indications:
None listed
Contraindications:
None listed

Indications:
None listed
Contraindications:
Underlying condition with
< 6 mo to live
Immunocompromised
Survival unlikely
> 60 min CPR, severe
lactic acidosis,
unrecoverable
multiorgan failure
Severe vasodilatory shock
Severe hemorrhage
Coagulopathy
Intracranial hemorrhage or
uncontrolled extracranial
hemorrhage
Aortic dissection
Not a VAD or transplant
candidate (severe liver
disease, ESRD,
advanced malignancy)
Recent advance directives
Age > 70 y
Substance abuse
Known medical
noncompliance
Deﬁnite poor prognosis for
neurologic recovery

Indications (eCPR):
Arrest < 50 min
Age < 65 y
No major comorbidities
(ESRD, liver failure,
COPD, CHF) or preexisting major
neurologic deﬁcits
BMI appropriate for Lucas
device
No history or evidence of
recreational drug use
Nontraumatic arrest
Witnessed arrest
Initial shockable rhythm or
signs of life with CPR
Presumed cardiac arrest (ie,
no obvious alternate
cause) or overdose of
cardiac toxins (eg, bblocker)
ETCO2 > 10 mm Hg

Indications:
Post-cardiotomy: Failure to wean from
bypass, low cardiac output,
intractable dysrhythmia, pulmonary
hypertension
Nonsurgical cardiac failure:
myocarditis, cardiomyopathy, low
output syndrome
Accidental hypothermia
Contraindication:
Advanced age > 65 y
Weight < 40 kg
BMI > 40
Femoral artery size < 5.5 mm
Chronic organ dysfunction
Prolonged CPR > 30 min
Malignancy
Clinically active bleeding
Recent or expanding intracranial bleed
Signiﬁcant coagulopathy
Immunosuppression (ANC < 400 mm3)
Sepsis
Severe irreversible brain damage
Severe burn
Clinical futility
 Cardiac index < 1 L/min/m2 got VVECMO
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Table 4. Key-element narrative reviewdpatient selection for VA-ECMO
Institution 1

ACS, acute coronary syndrome; ACLS, advanced cardiovascular life support; ANC, absolute neutrophil count; BMI, body mass index; CHF, congestive heart failure; CNS, central nervous system; COPD, chronic
obstructive pulmonary disease; CPR, cardiopulmonary resuscitation; DNR, do not resuscitate; ECMO, extracorporeal membrane oxygenation; eCPR, extracorporeal CPR; ESRD, end-stage renal disease; ETCO2, endtidal carbon dioxide; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; MI, myocardial infarction; PE, pulmonary embolism; PCI, percutaneous coronary intervention; SAVE, survival
after VA-ECMO; VA, veno-arterial; VAD, ventricular assist device; VV, veno-venous.
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Table 5. Key-element narrative review e patient selection for VV-ECMO
Institution 1
Indications:
Refractory hypoxic or hypercarbic
respiratory failure
PaO2/FiO2 < 60 on FiO2 100% and
PEEP > 16; pH < 7.2, respiratory
acidosis, regardless of PCO2
Acute or impending respiratory
collapse (blocked airway, status
asthmaticus that is unresponsive to
optimal care)
Contraindications:
Mechanical ventilation on high settings
for > 7 d; RESP score < e 6
Relative contraindications:
Nonrecoverable advanced comorbidity
such as major CNS damage or
terminal malignancy
Contraindication to anticoagulation
(eg, recent CNS hemorrhage or large
ischemic stroke)
Age > 75 y

Institution 2

Institution 5

Institution 6

Institution 7

Indications:
None listed
Contraindications:
None listed

Indications:
None listed
Contraindications:
None listed

Indications:
P/F ratio < 50 for 3 h
P/F ratio < 80 for 6 h
pH < 7.25 and pCO2 > 60 for 6 h
with up to 35 breaths/min with plat
pressure < 32 cm H2O
Contraindications:
Age > 65 y
Duration mechanical ventilation > 7 d
Pre-existing chronic lung disease
requiring chronic O2 support or
NIV support
Moribund or SAPS-II > 90
Irreversible neurologic injury
Coma following cardiopulmonary
arrest
Inadequate venous access
Coagulopathy
Severe distributive shock
Severe coexisting comorbidities
expected to limit life expectancy

Indications:
None listed
Contraindications:
Signs of intracranial
hemorrhage or other
contraindication to
anticoagulation
HIT
Lack of commitment to
ongoing aggressive
treatment
Underlying condition
limiting life expectancy
Relative contraindications
to consider (age > 55 y,
BMI < 20,
immunocompromised)

Institution 12
Indications:
None listed
Contraindications:
None listed

Institution 13
Indications:
< 7 d high setting
mechanical ventilation
Berlin deﬁnition of severe
ARDS
Reversible lung injury
Isolated lung injury
Contraindication:
Advanced age > 65 y
Weight < 40 kg
BMI > 40
Femoral artery size < 5.5
mm
Chronic organ dysfunction
Prolonged CPR > 30 min
Malignancy
Clinically active bleeding
Recent or expanding
intracranial bleed
Signiﬁcant coagulopathy
Immunosuppression (ANC
< 400 mm3)
Sepsis
Severe irreversible brain
damage
Severe burn
Clinical futility

ANC, absolute neutrophil count; ARDS, acute respiratory distress syndrome; BMI, body mass index; CNS, central nervous system; CPR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane
oxygenation; FiO2, fraction of inspired oxygen; HIT, heparin-induced thrombocytopenia; NIV, noninvasive ventilation; PaO2, partial pressure of oxygen; pCO2, partial pressure of carbon dioxide; PEEP, positive endexpiratory pressure; P/F, PaO2/FiO2; RESP score, respiratory ECMO survival prediction; SAPS, Simpliﬁed Acute Physiology Score; VV, veno-venous.
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Institution 3

Institution 4

Heparin bolus 10,000
Reference to heparin
Refers to heparin
e30,000 units given
protocol/order set is
protocol with
with
made, but no
speciﬁc monitoring
cannulationDedicated
speciﬁc details for
parameters
heparin protocol with
“non surgical”
depending on the
target PTT 50-64 s
patients
type of device
5000e10,000 unit bolus is Implies case-by-case
PTT (range: 50e70.9
recommended for
decision for posts) and Anti Xa
weaning ﬂows below 1.5
cardiotomy
(range: 0.3e0.5 U/
LPM
anticoagulation
mL) used for
Bivalirudin or argatroban
ECMO, Tandem
speciﬁed as alternate
Heart, Impella,
anticoagulation for HIT
Cardiowest, and
LMWH is suggested for
Heartmate
stable patients
ACT (range: 160
e180) used for
ECMO, Tandem
Heart, and Impella

Institution 5

Institution 6

Institution 8

Institution 9

Institution 12

Institution 13

5000-unit bolus of Recommends
50e100 units/kg at the
Starts at rate 15 units/ Speciﬁes heparin to Daily checklist for
heparin given for
targeting ACT
time of cannulation and
be given on
kg/h with a target
anticoagulation
referring to ACS
cannulation
160e200 s to be
continuous heparin
PTT of 50e70
cannulation, but
protocol or
No maintenance
achieved with
infusion thereafter
no further details
providerprotocol, but
heparin
Recommends targeting
Uses bivalirudin in
speciﬁed targets
refers to
ACT 1.5  upper limit
cases of HIT
Prespeciﬁed
maintenance
of normal for speciﬁc
parameters for
PPO that may
device (per ELSO)
INR and
contain this
Then speciﬁes targeting
ﬁbrinogen aimed
information
ACT 200e250 with
at correcting
ACT Plus or ACT 2;
coagulopathy
suggesting that typically
this would be achieved
with 20e40 units/kg/h
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Table 6. Key-element narrative reviewdanticoagulation protocol
Institution 1

ACS, acute coronary syndrome; ACT, activated clotting time; ECMO, extracorporeal membrane oxygenation; ELSO, Extracorporeal Life Support Organization; HIT, heparin-induced thrombocytopenia; INR,
international normalized ratio; LMWH, low-molecular-weight heparin; LPM, liters per minute; PPO, preferred provider organization; PTT, partial thromboplastin btime.

Table 7. Key-element narrative reviewdventilator management
Institution1
Discusses philosophy of lungprotective ventilation, but
acknowledges lack of evidence
Provides initial strategy using PC
ventilation targeting PC þ PEEP <
30 cm H2O, PEEP 10e14, rate 4
e8, Vt 3e4 mL/kg, FiO2 < 50%,
O2sat > 85%, pH > 7.25
Can consider extubation in select cases
with goal of liberating sedation, etc.

Institution 3
Suggests protective lung strategies
should be employed with patients
on VV-ECMO
Speciﬁcally suggest PC mode with
Pinsp < 25 cmH2, RR 8e10, PEEP
8e12, FiO2 < 0.3

Institution 4
Order set is provided
for physician to
prescribe ventilator
settings

Institution 6

Institution 12

Institution 13

Provides suggested parameters aimed at
preventing ventilator-induced lung
injury
Speciﬁcally suggests Pinsp < 20e25
cm H2O, PEEP < 10e15 cm H2O,
FiO2 0.3e0.4, O2sat > 85%, avoid
recruitment maneuvers
Goal PaO2 > 60 mm Hg, PaCO2
adjust sweep to achieve pH 7.35
e7.45

Suggests PC or VC aimed at lungprotective strategy
Speciﬁcally suggests tidal volume 4e6
mL/kg with plateau pressures < 25
cm H2O, PEEP 5e10 cm H2O,
FiO2 < 0.5
Consider recruitment maneuvers if
indicated only after acute lung
inﬂammation has subsided.
Physician order is required.

Ventilator parameters
chosen at the
discretion of the
ECLS team with no
prespeciﬁed
parameters

ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation; FiO2, fraction of inspired oxygen; O2 sat, oxygen saturation; PaCO2, partial pressure of carbon dioxide; PaO2, partial pressure of
oxygen; PC, pressure-controlled; PEEP, positive end-expiratory pressure; Pinsp, inspiratory pressure; RR, respiratory rate; VC, vital capacity; VV, veno-venous.
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Table 8. Key element narrative reviewdweaning protocol for VA-ECMO
Institution 1
Daily assessment by team for weaning
appropriateness
Gradual ECMO ﬂow decrease to 2
LPM. Further weaning should be
done in conjunction with
echocardiographic assessment and
with heparin bolus for ﬂows < 1.5
LPM.

Institution 2

Institution 3

Institution 4

Institution 6

Institution 12

Gradually wean ﬂows in 0.5 L
increments to an idle ﬂow of 2 LPM
or 2.5 LPM if not adequately
anticoagulated
Can brieﬂy decrease ﬂow to 1.5 LPM
to facilitate echocardiographic
assessment if adequately
anticoagulated.
Once ﬂows reduced, wean circuit FiO2
and sweep gas q2h to patient SvO2
60e70, lactate < 2, and normal PA
PO2 (100e190).
Once cardiac function is improved and
decannulation is planned, maintain
circuit ﬂow at minimum 2 LPM
until decannulation
Ventilator settings must be maintained
below (ﬁO2 < 0.5, Pplat < 25,
PEEP < 12)

Process described only
for VV-ECMO

Provides hemodynamic and echo
criteria to consider weaning.
Hemodynamic:
 Pulse pressure > 20 mm Hg for 24
h
 MAP > 60 with no vasopressors or
low dose of a single vasopressor. No
inotropes.
 CVP < 18e20 mm Hg

Process described only
for VV-ECMO

Suggest consider weaning when patient
shows signs of recovery such as
pulsatility or recovery on ECHO
No speciﬁc details about assessment for
weaning

Echocardiographic:

LVEF > 20-30%
LVOT VTI > 10 cm
PF > 200

Provides parameters for monitoring post decannulation.

CVP, central venous pressure; ECHO, echocardiogram; ECMO, extracorporeal membrane oxygenation; FiO2, fraction of inspired oxygen; LPM, liters per minute; LVEF, left ventricular ejection fraction; LVOT
VTI, left ventricular outﬂow tract velocity time integral; MAP, mean arterial pressure; PA, pulmonary artery; PaO2, pulmonary artery partial pressure of oxygen; PEEP, positive end-expiratory pressure; PF, PaO2/FiO2;
Pplat, plateau pressure; SvO2; venous oxygen saturation; VA, veno-arterial; VV, veno-venous.

Table 9. Key-element narrative reviewdweaning protocol for VV-ECMO
Institution 1
Daily assessment by team
for weaning
appropriateness
Perfusionist weans oxygen
ﬂow and sweep, while
respiratory therapist
optimizes ventilator
parameters

Institution 2

Institution 3

Institution 4

Institution 6

Institution 12

Daily assessment of need for ECMO
Wean ﬂows to 2 LPM or 2.5 LPM if
not anticoagulated
Wean FiO q2h for SaO2 > 92%
ABG q4h to wean sweep for CO2 35
e45
Once FiO2 at 0.21 and sweep ﬂow at
0.05-.1L, cap oxygenator
Observe patient for at least 12 h
(preferably 24) before consideration
of decannulation
Ventilator settings must be maintained
below (ﬁO2 < 0.5, Pplat < 25,
PEEP < 12)

Decrease pump ﬂows incrementally by
0.5 LPM with goal to achieve 2
LPM
Consider increasing anticoagulation
therapy to facilitate low ﬂows. Do
not ﬂow below 0.5 LPM
Once ﬂows of 2 LPM, wean FiO2 to
0.5. Consider off ECMO trial at this
point
Goal is to achieve PaO2 > 60 mm Hg
with vent FiO2 < 0.5 and Insp Plat
pressure < 30 cm H2O for 12e24 h
If successful, then consider
decannulation

Process described only for
VA-ECMO

Turn down sweep and FiO2
increments of 0.5 LPM and FiO2
0.1 while following ABG to
maintain PaO2 > 60 and PaCO2 to
target pH 7.35e7.45
Successful trial of off ECMO when
FiO2 and sweep can be maintained
at 0 for > 30 min

Process described only for
VV-ECMO

ABG, arterial blood gas; ECMO, extracorporeal membrane oxygenation; FiO2, fraction of inspired oxygen; Insp Plat, inspiratory plateau pressure; LPM, liters per minute; PaCO2, partial pressure of carbon dioxide;
PaO2, partial pressure of oxygen; PEEP, positive end-expiratory pressure; Pplat, plateau pressure; SaO2, oxygen saturation, VA, veno-arterial; VV, veno-venous.
CJC Open
Volume 4 2022

Fagan et al.
ECLS Protocol Project

531

provides an opportunity for national collaboration on ECLS
program development.
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